Executive Change: Prilenia Therapeutics B.V. Appoints Frederick Munschauer III, MD, MSc, FAAN, as Chief Medical Officer

Boston, MA – Prilenia Therapeutics has announced the appointment of Rick Munschauer as Chief Medical Officer. About Prilenia Therapeutics: Prilenia Therapeutics B.V. is a private, clinical-stage biopharmaceutical company focused on developing new treatments for Huntingtons disease (HD), amyotrophic lateral sclerosis (ALS), and other devastating neurodegenerative disorders. It is incorporated in the Netherlands and operates across the United States, Canada, Europe, and Israel, reflecting an international footprint and positioning in the global biotech market. The company is driven by a strong commitment to scientific excellence and patient-focused innovation, with a clear mission to develop and provide sustainable access to transformative medicines for people affected by these conditions. Prilenias lead investigational medicine is pridopidine, an orally administered, highly selective sigma-1 receptor agonist designed to stimulate key neuroprotective pathways that are impaired in neurodegenerative diseases, and it is being evaluated in late-stage clinical trials, including the Phase 3 PROOF-HD and confirmatory PRECISE-HD studies in Huntingtons disease. Notably, pridopidine has received Orphan Drug designation in HD and ALS in both the U.S. and EU, as well as FDA Fast Track designation for HD, and Prilenia is backed by leading life sciences investors, underscoring both its scientific potential and its recognized position within the neurodegeneration therapeutic landscape.

For more information visit: https://prilenia.com/

Prilenia Therapeutics
Address Unavailable
Boston, MA 2110
Phone: 31 35 808 0509
LinkedIn: https://www.linkedin.com/company/prilenia

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved